Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib

Marzia Del Re a, Stefania Crucitta a, Claudia Omarini b, Irene Bargagna c, Marta Mongillo d, Michela Palleschi e, Stefania Stucci f, Icro Meattini g,h, Raffaella D’Onofrio b, Giulia Lorenzini c, Pamela Biondani i, Ugo De Giorgi e, Camillo Porta f, Lorenzo Livi g,h, Salvatore Natalizio b, Andrea Fontana e, Elena Giontella d, Lucia Angelini g,h, Stefano Fogli b, Romano Danesi a

a Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Italy
b Division of Medical Oncology, University of Modena, Italy
c Unit of Medical Oncology, Department of Translational Research and New Technologies in Medicine, University of Pisa, Italy
d Section of Oncology, Department of Medicine, University of Verona and University and Hospital Trust of Verona, Italy
e Unit of Medical Oncology, IRCCS-Istituto Romagnolo per lo Studio dei Tumori (IRST) ‘Dino Amadori’, Meldola, Italy
f Division of Oncology, Department of Biomedical Sciences and Human Oncology, University of Bari, Italy
g Department of Experimental and Clinical Biomedical Sciences ‘M. Serio’, University of Florence, Italy
h Radiation Oncology Unit e Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy

ARTICLE INFO

Keywords: Breast cancer Ribociclib Proton pump inhibitors Drug-drug interactions PFS

ABSTRACT

Background: Gastric pH changes by proton-pump-inhibitors (PPIs) were found to affect progression-free survival (PFS) in metastatic breast cancer (mBC) patients treated with palbociclib. The current study was aimed at investigating whether the same effect could occur in patients treated with ribociclib.

Patients and methods: Patients with hormone-positive/HER-2-negative mBC candidates for first-line treatment with ribociclib were enrolled in this retrospective-cohort study. Patients were classified as “no concomitant PPIs” or “concomitant PPIs”; PPI administration covered the entire or not less than 2/3 of treatment with ribociclib. All clinical interventions were made according to clinical practice.

Results: A total of 128 patients were consecutively enrolled in the study; 78 belonged to the “no concomitant PPIs” group and 50 to the “concomitant PPIs” group. One hundred and six patients were endocrine-sensitive and received ribociclib and letrozole, while 22 were endocrine-resistant and were treated with ribociclib and fulvestrant. The most prescribed PPI was lansoprazole. According to PFS, patients taking PPIs had a PFS almost superimposable to those assuming ribociclib and endocrine therapy alone (35.3 vs. 49.2 months, p = 0.594). No difference in PFS was observed in estrogen-sensitive or estrogen-resistant mBC in the presence or absence of concomitant PPI treatment (p = 0.852). No correlation with adverse events was found including grade>$2 hematological toxicities.

Conclusions: The present study supports the hypothesis that the concomitant use of PPIs does not compromise the efficacy of ribociclib in a real-life setting.

1. Introduction

CDK4/6 inhibitors, including abemaciclib, palbociclib, and ribociclib, represent the standard of care in the I/II-line treatment of hormone receptor (HR)-positive/HER-2-negative metastatic breast cancer (mBC) [1–11]. Gastric pH changes by proton pump inhibitors (PPIs) may alter the oral bioavailability of targeted agents that exhibit pH-dependent solubility [3,4]; however, the clinical impact of such interaction remains a controversial topic that is currently debated [12]. In line with findings showing that co-administration of rabeprazole reduced palbo-

* Corresponding author. Department of Clinical and Experimental Medicine, Via Roma, 55, 56126, Pisa, Italy.
E-mail address: stefano.fogli@unipi.it (S. Fogli).

https://doi.org/10.1016/j.breast.2022.10.005
Received 10 August 2022; Received in revised form 20 September 2022; Accepted 12 October 2022
Available online 15 October 2022
0960-9776/© 2022 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
metastatic breast cancer patients treated with palbociclib [13]. Nonetheless, the effect of acid-reducing agents may depend on the anticancer drug used. According to this, ribociclib exhibit different dissolution properties from palbociclib, and its absorption is unlikely to be affected by changes in gastric pH by PPIs [14,15].

In the current study, we retrospectively evaluated the impact of PPI use on PFS of breast cancer patients treated with ribociclib in the clinical practice.

2. Patients and methods

This is a retrospective-cohort study carried out by reviewing medical charts on HR-positive/HER2-negative mBC patients treated with ribociclib as first-line treatment in the presence or absence of concomitant PPI therapy. The primary endpoint was to assess possible differences in progression-free survival (PFS) between PPI users and non-users. A list of potential study patients was obtained from the Divisions of Medical Oncology at the University of Modena and the University of Bari (Italy), the Units of Medical Oncology at the University of Pisa (Italy), the University of Verona and IRCCS-Istituto Romagnolo per lo Studio dei Tumori (IRST) ‘Dino Amadori’ (Italy), the Department of Experimental and Clinical Biomedical Sciences ‘M. Serio’ at the University of Florence (Italy), and the Radiation Oncology Unit from Azienda Ospedaliero Universitaria Careggi (Italy). Hormone status was defined as tumors with estrogen and/or progesterone receptor expression $>1\%$ and HER2-negative (score 0 or 1+ to immuno-histochemistry). Treatment groups were defined as “no concomitant PPIs” if no PPIs were administered during ribociclib treatment, or “concomitant PPIs” if the administration of PPIs covered the entire or not less than 2/3 of treatment with ribociclib. We only included patients who were previous users of PPIs and excluded those given these treatments after initiating ribociclib. According to the duration of previous endocrine response, endocrine sensitive patients were those who relapsed $>12$ months after the completion of adjuvant endocrine therapy or with de novo advanced breast cancer, whereas endocrine-resistant patients were those who relapsed $<12$ months after ending adjuvant endocrine therapy [14]. Pharmacological and clinical interventions were carried out according to clinical practice. In particular, ribociclib was administered orally at a dose of 600 mg, once daily for 21 days on/7 days off in 28-day cycles, plus endocrine therapy (ET, fulvestrant, or letrozole), according to clinical practice. Ribociclib reduction to 400 or 200 mg was made according to the toxicity profile. Patients took the dose of lansoprazole (15 mg), esomeprazole (20 mg), omeprazole (10 mg), or pantoprazole (20 mg) in the morning at breakfast. Ribociclib was taken at lunchtime and patients were advised not to take strong inhibitors or inducers of cytochrome P450 3A4 (CYP3A4). The prescribing physician monitored the patient’s compliance with the recommendations. Toxicity was graded according to Common Terminology Criteria for Adverse Events (CTCAE v5). The study was approved by the local Ethics Committee and conducted following the Helsinki Declaration. All patients released written informed consent.

3. Statistical analysis

This cohort study set out to collect data from at least one hundred HR-positive/HER2-negative mBC patients treated with ribociclib in the presence or absence of concomitant PPI therapy. Categorical variables including Eastern Cooperative Oncology Group (ECOG) performance status, hormone sensitivity, pre/peri-menopausal status, visceral/bone disease, and the number of tumor sites were described by absolute and relative frequencies, while quantitative parameters were described by median values and range. Baseline characteristics of patients who received ribociclib with or without PPIs were assessed by the Wilcoxon rank-sum test and chi-squared test. PFS was defined as the time from treatment start to the disease progression. Survival curves were obtained by Kaplan–Meier method, and differences between curves were assessed using the log-rank test. The evaluation of independent risk factors for PFS was performed by Cox hazard regression model. At least 84 PFS events were expected to be sufficient to detect the treatment effect with 90% statistical power (5% type I error rate) with a hazard ratio (HR) set at 1.8. Differences were considered significant at $p < 0.05$. All statistical analyses were carried out using MedCalc Statistical Software version 14.8.1 (MedCalc Software, bvba, Ostend, Belgium).

4. Results

A total of 128 patients were included in the present study. Fifty patients received concomitant PPI during ribociclib treatment, while 78 patients were treated with the association of ribociclib plus ET. One hundred and six patients were endocrine-sensitive and were administered a combination of ribociclib and letrozole, and 22 were defined as endocrine-resistant and were treated with the combination of ribociclib and fulvestrant. Seventy-seven patients received ribociclib at a dose of 600 mg (60.1%), 36 patients (28.1%) reduced the dose to 400 mg, and 7 (5.5%) needed the 200 mg dose.

There were no significant differences between “concomitant PPIs” and “no concomitant PPIs” groups in terms of baseline characteristics.

| Table 1 | Clinical characteristics of patients and distribution across PPI treatment groups. |
|---------|----------------------------------------------------------------------------------|
|          | Total of patients (n = 128) | Concomitant use of PPIs | p-value |
|          |                             | No (n = 78) | Yes (n = 50)  |
| Age at the diagnosis of metastasis, median (range) | 59 (35-85) | 58 | 64 | – |
| Pre/Postmenopause, n (%) | 31 (24.2) | 18 | 13 | 0.87 |
| PPIs use on PFS of breast cancer patients treated with ribociclib in the clinical practice. | 97 (75.8) | 60 | 37 | – |
| ECOG PS, n (%) | 0 | 94 (73.4) | 62 | 32 | 0.09 |
| 1 | 26 (20.3) | 11 | 15 | – |
| Disease site, n (%) | 2 | 8 (6.3) | 5 | 6 (4.6) | – |
| Visceral | 67 (52.3) | 41 | 26 | – |
| Non-visceral | 61 (47.7) | 37 | 24 | – |
| Type of ET associated to ribociclib, n (%) | Fulvestrant | 19 (14.8) | 13 | 6 (12) | – |
| Letrozole | 109 (85.2) | 65 | 44 | 0.64 |
| Endocrine sensitive or resistant disease, n (%) | 106 (82.8) | 62 | 44 | 0.88 |
| Sensitive | 22 (17.2) | 16 | 6 (12) | 0.31 |
| Resistant | 77 (60.1) | 48 | 29 | 0.06 |
| Dose reduction of ribociclib, n (%) | 400 mg | 36 (28.1) | 23 | 13 | – |
| 200 mg | 7 (5.5) | 1 (1.3) | 6 (12) | – |
| Unknown | 8 (6.3) | 6 (7.7) | 1 (2) |
| PPI use, n (%) | Lansoprazole | 34 | 34 | 0.68 |
| Omeprazole | 6 (12) | 6 | – |
| Pantoprazole | 7 (14) | 7 | – |
| Esomeprazole | 3 (6) | 3 | – |

ECOG PS, Eastern Cooperative Oncology Group (ECOG) performance status; ET, endocrine therapy; PPIs, proton pump inhibitors.
Furthermore, the Kaplan-Meier curves were almost superimposable between the two groups with no statistically significant difference in PFS (35.3 vs. 49.2 months in PPI users vs. non-users, respectively; HR 1.18, 95% CI 0.64–2.15; p = 0.594; Fig. 1).

The univariate analysis on age, number of metastatic sites at ribociclib baseline, endocrine sensitivity or resistance, ECOG, menopausal status, visceral disease, and ribociclib dose reduction showed that these variables were not significantly associated with PFS (Table 2).

To further evaluate the role of PPIs over endocrine sensitivity in PFS determination, patients were stratified into endocrine-sensitive patients (with or without concomitant PPIs) and endocrine-resistant patients (with or without concomitant PPIs). There was no statistically significant difference among endocrine-sensitive or resistant patients in the presence or absence of concomitant PPIs (HR 1.22, 95% CI 0.63–2.39; HR 1.37, 95% CI 0.30–6.16; Fig. 2A and B). No correlation with adverse events was found, particularly with grade >2 hematological toxicities since neutropenia, anemia, and thrombocytopenia were equally distributed across the two groups of patients and the majority of them developed toxicity during the first and/or second cycle of therapy (p = 0.493).

5. Discussion

Evidence from the present study suggests that the concomitant use of PPIs and ribociclib in metastatic breast cancer patients does not affect PFS. This appears to be a drug-specific property rather than a class effect since PPIs were found to substantially reduce PFS in metastatic breast cancer patients treated with palbociclib [13].

The different chemical behavior of the two CDK4/6 inhibitors in the gastric microenvironment may be due to dissolution properties rather than their acid-base properties. Structurally, ribociclib is a 2-amino-pyrrolo[2,3-d]pyrimidine derivative, whereas palbociclib is a pyrido[2,3-d]pyrimidine analogue [15]. Although they are both weak bases, ribociclib solubility is higher than 2.4 mg/ml at pH 4.5 (i.e. gastric pH values typically achieved by PPIs) [16], while that of palbociclib decreases to less than 0.5 mg/ml at pH > 4.5 [17]. To support this notion, an integrated approach, including noncompartmental analysis of clinical trial data and population pharmacokinetic analysis, indicated no effect of gastric pH changes on ribociclib pharmacokinetics [16]. Consistent with the findings of the current study, sensitivity analyses based on physiologically-based pharmacokinetic modeling showed that ribociclib exposure was independent of gastric pH in the physiologic range (1.0–8.0) [18]. Furthermore, short-term treatment with ranibizumab substantially reduced palbociclib Cmax [17], while no change in ribociclib bioavailability and/or steady-state pharmacokinetic parameters were observed in patients taking gastric pH-modifying agents [16,19].

It has also been reported that the free average steady-state

**Table 2**

Univariate analysis for PFS.

| Variables                                | HR (95% CI) | p-value |
|------------------------------------------|-------------|---------|
| Age (years)                              |             | 0.36    |
| ≤ 59 Reference                           |             |         |
| > 59                                     | 0.74 (0.40–1.38) |         |
| Number of metastatic sites               |             | 0.12    |
| 1 Reference                              |             |         |
| > 1                                      | 1.27 (0.94–1.70) |         |
| Endocrine sensitive or resistant disease |             | 0.48    |
| Sensitive Reference                      |             |         |
| Resistant                                | 1.32 (0.62–2.83) |         |
| ECOG PS                                  |             | 0.09    |
| 0 Reference                              |             |         |
| 1–2                                     | 1.81 (0.92–3.55) |         |
| Pre/Post-menopause                       |             | 0.70    |
| Pre-menopause                            |             |         |
| Post-menopause                           | 0.88 (0.45–1.71) |         |
| Visceral or non-visceral disease         |             | 0.34    |
| Non-visceral                             |             |         |
| Visceral                                 | 1.35 (0.73–2.49) |         |
| Dose reduction                           |             | 0.21    |
| No Reference                             |             |         |
| Yes                                      | 0.72 (0.43–1.20) |         |
| Concomitant use of PPIs                  |             | 0.59    |
| No Reference                             |             |         |
| Yes                                      | 1.17 (0.65–2.14) |         |

CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group (ECOG) performance status; PPIs, proton pump inhibitors; HR, hazard ratio.
have reduced sample size, such an approach has also been applied in compared to non-users, e.g., alimentary disorders or unhealthy conditions associated with worse outcomes in breast cancer, and the lack of information about fed or fasting conditions during PPI administration. Regarding the latter, ribociclib absorption is unlikely to be affected by changes in gastric pH following food intake, and the bioequivalence of ribociclib exposure with or without a high-fat meal has been demonstrated in a clinical trial [16].

Overall, our results support the hypothesis that long-term treatment with PPIs does not compromise the efficacy of ribociclib. Although we were unable to evaluate ribociclib pharmacokinetics, the lack of impact of PPIs on PFS in patients treated with this CDK4/6 inhibitor can be likely due to its greater tolerance to pH changes along with the broad therapeutic index that allowed to maintain plasma levels well above the minimum effective concentration. Such evidence may be relevant for clinical decision-making about the coadministration of PPIs in patients treated with ribociclib in a real-life setting.

Authors contribution statement

MDR, RD: conceptualization, methodology, investigation, data curation; SF, SC, MDR: writing – original draft preparation; CO, IB, MM, MP, SS, IM, RDO, GL, PB, UDG, CP, LL, SN, AF, EG, LA: collection of clinical data. SC, MDR: data Formal analysis; All: supervision, writing-reviewing and editing, conceptualization.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

None.

References

[1] Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: monaleesa-3. J Clin Oncol 2018;36:2465–72.
[2] Slamon DJ, Neven P, Chia S, et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Ann Oncol 2021;32:1015–24.
[3] Sledge Jr GW, Trii M, Neven P, et al. Monarch 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol 2017;35:2875–84.
[4] Hortobagyi GN, Stemmer SM, Buiris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 2016;375:1738–48.
[5] Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med 2022;386:942–50.

[6] Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol 2018;19:904–15.

[7] Im SA, Lu YS, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med 2019;381:307–16.

[8] Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med 2016;375:1925–36.

[9] Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 2016;17:425–99.

[10] Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med 2018;379:1926–36.

[11] Goetz MP, Toi M, Campone M, et al. Monarch 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 2017;35:3638–46.

[12] Meriggi F. Controversial link between proton pump inhibitors and anticancer agents: review of the literature. Tumori 2022;108:204–12.

[13] Del Re M, Omarini C, Diodati L, et al. Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. ESMO Open 2021;6:100231.

[14] Cardoso F, Senkus E, Costa A, et al. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4) dagger. Ann Oncol 2018;29:1634–57.

[15] Roskoski Jr R. Properties of FDA-approved small molecule protein kinase inhibitors. Pharmacol Res 2019;144:19–50.

[16] Samani TS, Dharua S, Lu Y, et al. Ribociclib bioavailability is not affected by gastric pH changes or food intake: in silico and clinical evaluations. Clin Pharmacol Ther 2018;104:374–83.

[17] Sun W, Klamerus KJ, Yuhas LM, et al. Impact of acid-reducing agents on the pharmacokinetics of palbociclib, a weak base with pH-dependent solubility, with different food intake conditions. Clin Pharmacol Drug Dev 2017;6:614–26.

[18] Hens B, Corsetti M, Spiller R, et al. Exploring gastrointestinal variables affecting drug and formulation behavior: methodologies, challenges and opportunities. Int J Pharm 2017;519:79–97.

[19] Lu Y, Yang S, Ho YY, Ji Y. Ribociclib-population pharmacokinetics and pharmacokinetic/pharmacodynamic analysis of neutrophils in cancer patients. J Clin Pharmacol 2021;61:1054–66.

[20] Goldstein MJ, Peters M, Weber BL, Davis CB. Optimizing the therapeutic window of targeted drugs in Oncology: potency-guided first-in-human studies. Clin Transl Sci 2021;14:536–43.

[21] Eser K, Onser AH, Eseer E, et al. Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study. BMC Cancer 2022;22:516.

[22] Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol 2018;29:1541–7.